Sqz Biotechnologies Co (SQZB)
Sqz Biotechnologies Co is a clinical-stage biotechnology company listed on OTC Markets under the ticker SQZB. The company is focused on developing cell-based therapies for cancer, infectious diseases, and other serious illnesses. Its lead program, SQZ-PBMC-HPV, is being studied in Phase I as both a standalone treatment and in combination with immuno-oncology agents for HPV16-positive advanced or metastatic solid tumors, including cancers of the cervix, head and neck, anus, penis, vulva, and vagina. The pipeline also includes SQZ-AAC-HPV and SQZ-eAPC-HPV, the latter of which is also in Phase I testing for similar HPV16-positive tumor settings. In addition, the company is advancing its SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers platforms. Sqz Biotechnologies was incorporated in 2013 and is based in Watertown, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-SQZB
|
—
|
—
|
—
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
—
|
—
|
—
|
707.787 K
|
—
|
—
|
—
|
—
|
—
|
—
|